Summary of Significant Accounting Policies - License Agreements - RareStone (Details)	1 Months Ended	3 Months Ended			12 Months Ended
	Dec. 31, 2021 USD ($) item	Mar. 31, 2024 USD ($)	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($) item	Mar. 31, 2022 USD ($)
Significant Agreements
Equity issued in conjunction with license agreement		$ 18,716,000
RareStone Group Ltd.
Significant Agreements
Number of independent sub studies in patients | item	4
RareStone Group Ltd. | License agreement
Significant Agreements
Number of performance obligations | item							2
License agreement commercial manufacturing supply discount					$ 1,286,000
Realized loss on RareStone equity			$ 1,040,000	$ 1,040,000
Loss on RareStone equity investment				300,000
Upfront consideration							$ 8,040,000
Contract with customer liability revenue recognized					$ 0	$ 6,754,000	0
Upfront payment	$ 7,000,000						7,000,000
Equity issued in conjunction with license agreement	1,077,586
Equity recorded at fair value				$ 1,040,000				$ 2,440,000
Aggregate payment upon achievement of development and commercial milestones	$ 62,500,000						$ 62,500,000